ICON PLC (ICLR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ICON PLC (ICLR) has a cash flow conversion efficiency ratio of 0.044x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($408.51 Million) by net assets ($9.33 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ICON PLC net asset quality index to measure how much of total assets are equity-financed.
ICON PLC - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how ICON PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of ICON PLC to evaluate the quality of earnings relative to operating cash generation.
ICON PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ICON PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MARKS SPENCER ADR LS-25
F:MA6A
|
N/A |
|
Persistent Systems Limited
NSE:PERSISTENT
|
0.052x |
|
YTO Express Group Co Ltd
SHG:600233
|
0.060x |
|
China Merchants Shekou Industrial Zone Holdings
SHE:001979
|
0.019x |
|
Jyske Bank A/S
CO:JYSK
|
-0.328x |
|
Universal Health Services Inc
NYSE:UHS
|
0.053x |
|
DEUTSCHE WOHNEN ADRS/1/2
F:DWNP
|
0.029x |
|
Dr. Reddy's Laboratories Limited
F:RDDA
|
0.029x |
Annual Cash Flow Conversion Efficiency for ICON PLC (1998–2024)
The table below shows the annual cash flow conversion efficiency of ICON PLC from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see ICLR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.52 Billion | $1.29 Billion | 0.135x | +7.54% |
| 2023-12-31 | $9.24 Billion | $1.16 Billion | 0.126x | +89.54% |
| 2022-12-31 | $8.50 Billion | $563.32 Million | 0.066x | -35.51% |
| 2021-12-31 | $8.07 Billion | $829.14 Million | 0.103x | -68.02% |
| 2020-12-31 | $1.85 Billion | $594.72 Million | 0.321x | +26.07% |
| 2019-12-31 | $1.62 Billion | $412.54 Million | 0.255x | +33.88% |
| 2018-12-31 | $1.39 Billion | $264.01 Million | 0.190x | -38.84% |
| 2017-12-31 | $1.23 Billion | $383.08 Million | 0.311x | +13.54% |
| 2016-12-31 | $945.17 Million | $259.20 Million | 0.274x | -25.03% |
| 2015-12-31 | $764.20 Million | $279.53 Million | 0.366x | +104.52% |
| 2014-12-31 | $950.21 Million | $169.95 Million | 0.179x | -26.38% |
| 2013-12-31 | $910.58 Million | $221.23 Million | 0.243x | +61.14% |
| 2012-12-31 | $754.58 Million | $113.77 Million | 0.151x | +408.94% |
| 2011-12-31 | $681.54 Million | $20.19 Million | 0.030x | -77.30% |
| 2010-12-31 | $670.00 Million | $87.43 Million | 0.130x | -70.72% |
| 2009-12-31 | $572.25 Million | $255.07 Million | 0.446x | +150.26% |
| 2008-12-31 | $456.37 Million | $81.28 Million | 0.178x | +61.55% |
| 2007-12-31 | $389.71 Million | $42.97 Million | 0.110x | -33.60% |
| 2006-12-31 | $303.86 Million | $50.45 Million | 0.166x | +192.11% |
| 2005-12-31 | $242.45 Million | $13.78 Million | 0.057x | -71.77% |
| 2004-12-31 | $216.76 Million | $43.64 Million | 0.201x | +11.01% |
| 2003-12-31 | $118.46 Million | $21.48 Million | 0.181x | +15.57% |
| 2002-12-31 | $136.91 Million | $21.48 Million | 0.157x | -12.45% |
| 2001-12-31 | $96.35 Million | $17.27 Million | 0.179x | +1011.45% |
| 2000-12-31 | $79.84 Million | $-1.57 Million | -0.020x | -118.03% |
| 1999-12-31 | $77.05 Million | $8.40 Million | 0.109x | +411.04% |
| 1998-12-31 | $70.30 Million | $1.50 Million | 0.021x | -- |
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more